A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.
A review article in Current Gastroenterology Reports summarized the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) and those in the pipeline. The review, intended as a guide for clinicians, provided resources to help clinicians navigate biosimilar use with their patients and stay up to date on the biosimilar landscape.
Despite availability of these lower-cost alternatives to the originator drugs they reference, the authors said that uptake “remains low” because of concerns about efficacy and safety and delayed market entry of biosimilars. However, they suggested clinicians “can effectively address some of these barriers.”
The authors included a table of biosimilar product characteristics with links to training videos and patient programs, plus a checklist for biosimilar adoption and utilization in practice which outlined recommended educational, workflow, and monitoring steps.
IBD includes Crohn disease (CD) and ulcerative colitis (UC), chronic conditions characterized by inflammation of the gastrointestinal tract. The authors noted that the incidence of IBD has doubled in recent years. Although there have been, ”significant advances made with IBD treatment to prevent disease progression and improve quality of life,” the cost of biologics is high due to the complexity of the development and manufacturing processes, they said. They added that financial burden on patients and health care systems “is anticipated to worsen given the growing population of patients with IBD needing effective biologic treatment.”
The reviewers began by explaining the concepts of biosimilarity, extrapolation, and the US FDA’s interchangeability designation. For example, biosimilars are not generics, because biologics are manufactured in living cells and producing an identical copy is not possible. There is inherent variability both between manufacturing lots of the reference product and between the reference product and biosimilars. The approval process for biosimilars involves demonstrating similarity to the originator molecule in structure, function, pharmacokinetics, and clinical efficacy and safety. The approval of a biosimilar can be extrapolated based on a comparative clinical efficacy and safety study in one condition to other conditions based on the same mechanism of action.
The reviewers noted the nocebo effect is a major barrier to biosimilar adoption and persistence, but that physician influence can mitigate the nocebo effect, citing previous research suggesting that over 80% of biosimilar discontinuations are due to the nocebo effect. Since patients with negative perceptions of biosimilars are at risk of the nocebo effect, and “many patients turn to their healthcare providers as the best source of medical information,” those perceptions can be influenced by their clinicians, the reviewers wrote. They provided strategies for clinicians to address the nocebo effect, such as “providing proactive biosimilar education and incorporating a shared decision-making process that addresses patients’ concerns while empowering them in their care.”
Infliximab biosimilars
The authors discussed 3 available infliximab biosimilars, infliximab-dyyb (Inflectra), the first
approved by the FDA for treating IBD in 2016, as well as infliximab-abda (Renflexis) and infliximab-axxq (Avsola). They added that an unbranded infliximab product produced by Janssen using the same cell line as the reference product is also available. Additionally, although most infliximab biosimilars are delivered intravenously, the first subcutaneous formulation of infliximab-dyyb (Zymfentra; Celltrion) was approved in October 2023.
Although infliximab biosimilars initially achieved approval for IBD by extrapolation from other conditions, “numerous studies have since then been conducted, providing reassuring data that infliximab biosimilars are effective, safe, and comparable to reference infliximab in IBD,” the authors said. They cited survey data showing that gastroenterologists have become more comfortable with infliximab biosimilars since they were first introduced in 2016 and that most gastroenterologists reported they have prescribed infliximab biosimilars.
Adalimumab biosimilars
As of April 2024, there are 10 adalimumab biosimilars approved by the FDA. Despite the first approval occurring in 2016, market entry was delayed by patent litigation until 2023. The reviewers noted that “adalimumab is one of the costliest biologics,” and the entry of adalimumab biosimilars to the market is expected to promote price competition and cost savings.
However, they noted, adalimumab biosimilars have “several layers of complexity” clinicians should be aware of. Product characteristics such as concentration, stability at room temperature, formulation, and inclusion of citrate and latex vary among adalimumab biosimilars. For example, citrate-free formulations and higher concentration, lower injection volume formulations aim to reduce injection site pain. Also, 3 adalimumab biosimilars have received the interchangeability designation: adalimumab-adbm (Cyltezo; Boehringer Ingelheim), adalimumab-ryvk (Simlandi; Alvotech/Teva) and adalimumab-afzb (Abrilada; Pfizer). The authors provided a table outlining these characteristics, saying “familiarity with each product will be important as this could drive patient preference and/or biosimilar product selection.”
Ustekinumab and other biosimilars
The first ustekinumab biosimilar (ustekinumab-auub, Wezlana; Amgen) with an interchangeability designation was approved by the FDA in November 2023, and it is indicated for moderate to severe CD or UC. Unfortunately, the authors wrote, ustekinumab-auub will not enter the market until 2025, “due to the settlement terms set by the manufacturer of reference ustekinumab.”
They added that several other ustekinumab biosimilars are currently in the pipeline, as are biosimilars to golimumab and natalizumab, whose patents are expected to expire in the next few years.
The future of biosimilars in IBD
According to the authors, although clinical research on biosimilars “objectively shows there is no decrease in safety or efficacy when compared to the respective reference products,” biosimilar integration into IBD care “has been hindered by several barriers.” As more biosimilars enter the market, they said, “clinicians continue to be important stakeholders and can significantly help improve biosimilar utilization in IBD in numerous ways.”
Reference
Angyal A, Bhat S. Biosimilars in IBD: What every clinician needs to know. Curr Gastroenterol Rep. 2024;26(3):77-85. doi:10.1007/s11894-023-00913-5
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
Biosimilars Gastroenterology Roundup for January 2024—Podcast Edition
February 4th 2024On this episode of Not So Different, we reminisce on all the major gastroenterology news from January, which brought several reports quantifying how the gastroenterology biosimilar market is progressing and marked the 1-year anniversary of adalimumab biosimilar competition in the US.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.